Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 25% less
These brands contain the same active ingredient (Sitagliptin + Metformin Hydrochloride). Same strength and form. Confirm the switch with your doctor or pharmacist.
Radiglip-M
Rx50 mg+500 mg • Tablet (Extended Release)
More from Radiglip-M
Other strengths and forms by Radiant Pharmaceuticals Ltd.
Indications & Uses
Sitagliptin + Metformin Hydrochloride is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, when treatment with both sitagliptin and metformin is appropriate. There are some important limitations of use. This should not be used in patients with type 1 diabetes, or to treat diabetic ketoacidosis, because it would not be effective in these settings. This has not been studied in patients with a history of pancreatitis. It is unknown whether such patients are at increased risk of developing pancreatitis while using this.
Pharmacology
This tablet combines two medicines that lower blood sugar in different ways, so together they help control glucose in people with type 2 diabetes. The two ingredients are Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Metformin HCl, which belongs to the biguanide class.
Sitagliptin is believed to work in type 2 diabetes by slowing the inactivation of incretin hormones. These hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The intestine releases them throughout the day, and their levels rise after a meal. The enzyme DPP-4 inactivates them quickly. They are part of an endogenous system that helps regulate glucose homeostasis in the body.
When blood glucose is normal or high, GLP-1 and GIP increase insulin synthesis and release from the pancreatic beta cells, through intracellular signalling pathways that involve cyclic AMP. GLP-1 also lowers glucagon secretion from the pancreatic alpha cells, which reduces glucose production in the liver. Because Sitagliptin increases and prolongs the levels of active incretins, it raises insulin release and lowers circulating glucagon, and it does this in a glucose-dependent way.
Metformin HCl works differently from the other classes of oral antihyperglycemic agents. It decreases hepatic glucose production, decreases glucose absorption from the intestine, and increases glucose uptake and utilization in the peripheral tissues.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Detailed dosing reference is not available yet. Please follow your prescription and consult your pharmacist.
Side Effects
In patients who started sitagliptin and metformin together, the most common adverse reactions were diarrhea, upper respiratory tract infection, and headache. These were reported in ≥5% of patients and happened more often than with placebo. When sitagliptin was given with a sulfonylurea and metformin, the adverse reactions reported in ≥5% of patients, and more often than with placebo plus a sulfonylurea and metformin, were hypoglycemia and headache. When sitagliptin was given with insulin and metformin, hypoglycemia was the only adverse reaction reported in ≥5% of patients and more often than with placebo plus insulin and metformin. With sitagliptin alone (monotherapy), nasopharyngitis was the only adverse reaction reported in ≥5% of patients and more often than with placebo. The most common adverse reactions (>5%) when metformin therapy is started are diarrhea, nausea/vomiting, fatulence, abdominal discomfort, indigestion, asthenia, and headache.
Cautions & Contraindications
Warnings & Precautions
Lactic acidosis Metformin can build up in the body and cause lactic acidosis. The risk goes up with conditions such as sepsis, dehydration, excess alcohol intake, hepatic insufficiency, renal impairment and acute congestive heart failure. Symptoms include malaise, myalgias, respiratory distress, increasing somnolence and nonspecific abdominal distress. Laboratory findings show a low pH, an increased anion gap and elevated blood lactate. If acidosis is suspected, stop this tablet and admit the patient to hospital immediately. In patients with hypothyroidism, thyroid-stimulating hormone (TSH) levels should be checked regularly. Long-term treatment with metformin has been linked with a fall in serum vitamin B12 levels, which may cause peripheral neuropathy, so the vitamin B12 level should be monitored. Others Do not use this tablet in patients with hepatic disease. Acute renal failure, sometimes needing dialysis, has been reported after the medicine came into general use. Before starting this tablet, and at least once a year after that, assess renal function and confirm it is normal. Acute pancreatitis has also been reported after marketing, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, stop this tablet promptly. Hematologic parameters should be measured every year. Warn patients against drinking too much alcohol. During periods of stress and reduced intake of fluids and food, such as with fever, trauma, infection or surgery, this tablet may need to be stopped and insulin used for a short time. Patients who were well controlled on this tablet but then develop laboratory abnormalities or clinical illness should be evaluated promptly for ketoacidosis or lactic acidosis. When this tablet is used with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be needed to reduce the risk of hypoglycemia. Serious allergic and hypersensitivity reactions have been reported after marketing in patients treated with sitagliptin (one of the components of this tablet). These include anaphylaxis, angioedema and exfoliative skin conditions, including Stevens-Johnson syndrome. In such cases, stop this tablet promptly, assess for other possible causes, set up appropriate monitoring and treatment, and start alternative treatment for diabetes. No clinical studies have given conclusive evidence that Sitagliptin Phosphate Monohydrate INN/Metformin Hydrochloride BP, or any other anti-diabetic drug, reduces macrovascular risk.
Contraindications
Sitagliptin + Metformin Hydrochloride tablet must not be given to people with kidney disease or poor kidney function. This may be suggested by a serum creatinine level of ≥1.5 mg/dL in males or ≥1.4 mg/dL in females, or by an abnormal creatinine clearance. Kidney function can also fall because of conditions such as cardiovascular collapse (shock), acute myocardial infarction and septicemia. It is also contraindicated in people with acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. People with a history of a serious hypersensitivity reaction to this tablet or to sitagliptin, such as anaphylaxis or angioedema, must not take it either. The tablet should be stopped temporarily in patients having radiologic studies that involve intravascular administration of iodinated contrast materials, because these products may suddenly change kidney function.
Pregnancy & Breastfeeding
Sitagliptin Phosphate Monohydrate INN/Metformin Hydrochloride BP is Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women with this combination or with either of its individual components, so its safety in pregnancy is not known. Use this tablet during pregnancy only if it is clearly needed.
It is not known whether sitagliptin passes into human milk. Many drugs do pass into human milk, so take caution when giving this tablet to a nursing woman.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Overdose
Sitagliptin: If someone takes an overdose, the usual supportive measures are reasonable. These include removing unabsorbed material from the gastrointestinal tract, monitoring the patient clinically (with an electrocardiogram), and giving supportive treatment according to the patient's clinical condition. Sitagliptin is modestly dialyzable, so prolonged hemodialysis may be considered if it is clinically appropriate. It is not known whether sitagliptin can be removed by peritoneal dialysis.
Metformin hydrochloride: Overdoses of metformin hydrochloride have happened, including cases where more than 50 grams was taken. Metformin is dialyzable, with a clearance of up to 170 mL/min when the patient's hemodynamic condition is good. For this reason, hemodialysis may help remove accumulated drug from patients in whom a metformin overdose is suspected. Pancreatitis may occur with a metformin overdose.
⚠️ In an emergency call 999 or go to the nearest hospital emergency department.
Storage
Keep Sitagliptin + Metformin Hydrochloride below 25°C, in a dry place and away from light. Store the medicine where children can't reach it. Don't use it after the expiry date. It should be dispensed only on the prescription of a registered physician.
Drug Interactions
Common questions about Radiglip-M 50 mg+500 mg
What is Radiglip-M 50 mg+500 mg Tablet (Extended Release)?
Radiglip-M 50 mg+500 mg Tablet (Extended Release) is a medicine that contains Sitagliptin + Metformin Hydrochloride. It is made by Radiant Pharmaceuticals Ltd. It belongs to the Combination Oral hypoglycemic preparations group of medicines.
What is Radiglip-M used for?
Sitagliptin + Metformin Hydrochloride is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, when treatment with both sitagliptin and metformin is appropriate. There are some important limitations of use.
What are the side effects of Radiglip-M?
In patients who started sitagliptin and metformin together, the most common adverse reactions were diarrhea, upper respiratory tract infection, and headache. These were reported in ≥5% of patients and happened more often than with placebo.
Can I take Radiglip-M during pregnancy or while breastfeeding?
Sitagliptin Phosphate Monohydrate INN/Metformin Hydrochloride BP is Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women with this combination or with either of its individual components, so its safety in pregnancy is not known. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
What happens if I take too much Radiglip-M?
Sitagliptin: If someone takes an overdose, the usual supportive measures are reasonable. These include removing unabsorbed material from the gastrointestinal tract, monitoring the patient clinically (with an electrocardiogram), and giving supportive treatment according to the patient's clinical condition. In an emergency call 999 or go to the nearest hospital emergency department.
How should I store Radiglip-M?
Keep Sitagliptin + Metformin Hydrochloride below 25°C, in a dry place and away from light. Store the medicine where children can't reach it.
Can I take other medicines with Radiglip-M?
Some medicines can interact with Sitagliptin + Metformin Hydrochloride, for example: Levothyroxine Sodium. Tell your doctor or pharmacist about every medicine you take.
Is there a cheaper medicine with the same ingredient?
Sitalia M XR by Delta Pharma PLC. has the same ingredient and strength for ৳15.00 per unit, compared with ৳20.00 for Radiglip-M. Ask your doctor or pharmacist before switching.
Do I need a prescription for Radiglip-M?
Radiglip-M is a prescription (Rx) medicine. Take it as your doctor advises.